Jain Rahul, Huda Taha I, Paul Srijit, Chobrutskiy Andrea, Chobrutskiy Boris I, Baker Madeline C, Goel Nandini, Blanck George
Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, Florida, USA.
Department of Pediatrics, Oregon Health and Science University Hospital, Portland, Oregon, USA.
Int J Cancer. 2025 Feb 1;156(3):652-658. doi: 10.1002/ijc.35212. Epub 2024 Oct 8.
Burkitt lymphoma (BL) has a tight association with Epstein-Barr virus (EBV), especially in sub-Saharan Africa. While the relationship between BL and EBV is well documented, the relationship between the anti-EBV adaptive immune response, particularly in sub-Saharan African cases, and disease course, has not been substantially investigated. An analysis of T-cell receptor (TCR) complementarity determining region-3 (CDR3) sequences, reported here, from EBV-positive, Ugandan BL tumor samples revealed a correlation between the presence of anti-EBV CDR3s and improved overall survival probabilities. Furthermore, chemical complementarity assessments demonstrated higher complementarity for TCR CDR3s and EBV epitopes in the cases where there had been a detection of the anti-EBV CDR3 AA sequence matches in the BL tumor samples. Overall, the results reported here raise the question of whether EBV targeted immunotherapy would lead to better BL outcomes?
伯基特淋巴瘤（BL）与爱泼斯坦-巴尔病毒（EBV）密切相关，尤其是在撒哈拉以南非洲地区。虽然BL与EBV之间的关系已有充分记录，但抗EBV适应性免疫反应与疾病进程之间的关系，特别是在撒哈拉以南非洲地区的病例中，尚未得到充分研究。本文报道了对来自乌干达EBV阳性BL肿瘤样本的T细胞受体（TCR）互补决定区3（CDR3）序列的分析，结果显示抗EBV CDR3的存在与总体生存概率的提高之间存在相关性。此外，化学互补性评估表明，在BL肿瘤样本中检测到抗EBV CDR3氨基酸序列匹配的情况下，TCR CDR3与EBV表位具有更高的互补性。总体而言，本文报道的结果提出了一个问题，即EBV靶向免疫疗法是否会带来更好的BL治疗结果？
